Design and Methods of a Randomized Trial of Continuous Glucose Monitoring in Persons with Type 1 Diabetes with Impaired Glycemic Control Treated with Multiple Daily Insulin Injections (GOLD Study)

Journal of Diabetes Science and Technology

Volumn 10, Issue 3, 2016, Pages 754-761

  Lind, Marcus ^a,b   Polonsky, William ^c   Hirsch, Irl B ^d   Heise, Tim ^e   Bolinder, Jan ^f   Dahlqvist, Sofia ^b   Pehrsson, Nils Gunnar ^g   Moström, Peter ^h  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b NU Hospital Organization   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e Profil   (Germany)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g Statistiska Konsultgruppen   (Sweden)

^h Section of Rheumatology   (Sweden)

Author keywords

CGM; glycemic control; quality of life; randomized trial; type 1 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN; C PEPTIDE; C REACTIVE PROTEIN; CREATININE; INSULIN; ANTIDIABETIC AGENT;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DIABETES TREATMENT SATISFACTION QUESTIONNAIRE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIA CONFIDENCE QUESTIONNAIRE; HYPOGLYCEMIA FEAR SURVEY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; PATIENT SATISFACTION; PHYSICAL ACTIVITY; PROBLEM AREAS IN DIABETES SCALE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION-5; ANALYSIS; BLOOD; CROSSOVER PROCEDURE; DEVICES; FEMALE; GLUCOSE BLOOD LEVEL; MALE; METHODOLOGY;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PATIENT SATISFACTION; QUALITY OF LIFE; RESEARCH DESIGN; SURVEYS AND QUESTIONNAIRES;

EID: 85009460356     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296816642578     Document Type: Article

References (36)

1. DCCT Study Group. The Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-986.
2. Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J., Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010;(1): CD005103.
3. Hansen MV, Pedersen-Bjergaard U, Heller SR, et al. Frequency and motives of blood glucose self-monitoring in type 1 diabetes. Diabetes Res Clin Pract. 2009; 85 (2): 183-188.
4. Miller KM, Beck RW, Bergenstal RM, et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care. 2013; 36 (7): 2009-2014.
5. Evans JM, Newton RW, Ruta DA, MacDonald TM, Stevenson RJ, Morris AD., Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ. 1999; 319 (7202): 83-86.
6. Hirsch I., Clinical review: realistic expectations and practical use of continuous glucose monitoring for the endocrinologist. J Clin Endocrinol Metab. 2009; 94 (7): 2232-2238.
7. Pickup JC, Freeman SC, Sutton AJ., Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011; 343: d3805.
8. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008; 359 (14): 1464-1476.
9. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012; 55 (12): 3155-3162.
10. Riveline JP, Schaepelynck P, Chaillous L, et al. Assessment of patient-led or physician-driven continuous glucose monitoring in patients with poorly controlled type 1 diabetes using basal-bolus insulin regimens: a 1-year multicenter study. Diabetes Care. 2012; 35 (5): 965-971.
11. Bradley C, Gilbride CJ., Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine. Diabetes Obes Metab. 2008; 10 (suppl 2): 50-65.
12. Bradley C., The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In: Bradley C, ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood; 1994.
13. Bradley C., Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care. 1999; 22: 530-532.
14. Anderbro T, Amsberg S, Wredling R, et al. Psychometric evaluation of the Swedish version of the Hypoglycaemia Fear Survey. Patient Educ Couns. 2008; 73 (1): 127-131.
15. Gonder-Frederick LA, Schmidt KM, Vajda KA, et al. Psychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes. Diabetes Care. 2011; 34 (4): 801-806.
16. Irvine A, Cox D, Gonder-Frederick L., The Fear of Hypoglycaemia Scale. In: Bradley C, ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood; 1994.
17. Polonsky WH, Anderson BJ, Lohrer PA, Welch G, Jacobson AM, Schwartz C., Assessment of diabetes-specific distress. Diabetes Care. 1995; 18: 754-760.
18. Amsberg S, Wredling R, Lins PE, Adamson U, Johansson UB., The psychometric properties of the Swedish version of the Problem Areas in Diabetes Scale (Swe-PAID-20): scale development. Int J Nurs Stud. 2008; 45: 1319-1328.
19. Hajos TR, Pouwer F, Skovlund SE, et al. Psychometric and screening properties of the WHO-5 well-being index in adult outpatients with type 1 or type 2 diabetes mellitus. Diabet Med. 2013; 30 (2): e63-e69.
20. Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003; 35 (8): 1381-1395.
21. Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000; 32 (9 suppl): S498-S504.
22. Hirsch IB., Insulin analogues. N Engl J Med. 2005; 352 (2): 174-183.
23. Jeppsson JO, Kobold U, Barr J, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med. 2002; 40 (1): 78-89.
24. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF., Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970; 19 (9): 644-655.
25. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014; 371 (21): 1972-1982.
26. Livingstone SJ, Looker HC, Hothersall EJ, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLOS MED. 2012; 9 (10): e1001321.
27. Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015; 313 (1): 37-44.
28. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353: 2643-2653.
29. Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015; 313 (1): 45-53.
30. Swedish National Diabetes Register. Annual report 2013. Available at: https://www.ndr.nu/pdfs/Annual-Report-NDR-2013.pdf. Accessed January 18, 2016.
31. Matuleviciene V, Joseph JI, Andelin M, et al. A clinical trial of the accuracy and treatment experience of the Dexcom G4 sensor (Dexcom G4 system) and Enlite sensor (guardian REAL-time system) tested simultaneously in ambulatory patients with type 1 diabetes. Diabetes Technol Ther. 2014; 16 (11): 759-767.
32. Damiano ER, McKeon K, El-Khatib FH, Zheng H, Nathan DM, Russell SJ., A comparative effectiveness analysis of three continuous glucose monitors: the Navigator, G4 Platinum and Enlite. J Diabetes Sci Technol. 2014; 8: 699-708.
33. Kropff J, Bruttomesso D, Doll W, et al. Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research centre and daily life conditions. Diabetes Obes Metab. 2015; 17 (4): 343-349.
34. Polonsky WH, Hessler D., Perceived accuracy in continuous glucose monitoring: understanding the impact on patients. J Diabetes Sci Technol. 2015; 9 (2): 339-341.
35. JDRF study group. Factors predictive of use and benefit from CGM in type 1 diabetes. Diabetes Care. 2009; 32 (11): 1947-1953.
36. Anderson J, Attvall S, Sternemalm L, et al. Effect on glycemic control by short- and long-term use of continuous glucose monitoring in clinical practice. J Diabetes Sci Technol. 2011; 5 (6): 1472-1479.